Deciphering the mystery of thalidomide teratogenicity

Area of Science:

• Pharmacology
• Developmental Biology
• Molecular Biology

Background:

• Thalidomide, initially a sedative, caused severe birth defects due to teratogenicity.
• Despite decades of research, thalidomide's precise molecular targets and mechanisms remain elusive.
• Current hypotheses include anti-angiogenesis and oxidative stress, but lack direct molecular evidence.

Purpose of the Study:

• To identify the direct molecular target of thalidomide responsible for its teratogenic effects.
• To elucidate the mechanism by which thalidomide induces limb malformations.

Main Methods:

• Development of ferrite-glycidyl methacrylate beads for magnetic separation and purification of ligand-binding molecules.
• Affinity purification using these beads to identify thalidomide-binding proteins.
• Functional studies using cereblon mutants in zebrafish and chick models.

Main Results:

• Cereblon was identified as a primary direct target of thalidomide.
• Cereblon forms part of an E3 ubiquitin ligase complex regulating fibroblast growth factor 8 (FGF8) expression.
• Inhibition of cereblon-E3 ligase activity by thalidomide leads to downregulation of FGF8 and subsequent limb malformations.

Conclusions:

• Thalidomide exerts its teratogenic effects by binding to cereblon and inhibiting its E3 ubiquitin ligase activity.
• This inhibition disrupts fibroblast growth factor 8 signaling, a critical pathway in limb development.
• Cereblon is a key molecule in understanding the longstanding mystery of thalidomide-induced birth defects.